Eventide Asset Management LLC held its position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 150,000 shares of the biotechnology company’s stock at the end of the first quarter. Eventide Asset Management LLC owned approximately 0.41% of CytomX Therapeutics worth $2,591,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Harbourvest Partners LLC bought a new position in CytomX Therapeutics during the fourth quarter valued at $110,000. Highbridge Capital Management LLC acquired a new position in shares of CytomX Therapeutics during the fourth quarter worth about $158,000. Hillsdale Investment Management Inc. acquired a new position in shares of CytomX Therapeutics during the first quarter worth about $159,000. Trexquant Investment LP acquired a new position in shares of CytomX Therapeutics during the fourth quarter worth about $186,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of CytomX Therapeutics during the first quarter worth about $206,000. 52.28% of the stock is currently owned by hedge funds and other institutional investors.
CytomX Therapeutics, Inc. (CTMX) traded down 2.89% during mid-day trading on Tuesday, hitting $13.78. 221,157 shares of the company traded hands. The firm’s market capitalization is $506.40 million. The firm has a 50 day moving average of $14.42 and a 200 day moving average of $13.71. CytomX Therapeutics, Inc. has a one year low of $9.10 and a one year high of $20.02.
CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Friday, May 5th. The biotechnology company reported ($0.23) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.55) by $0.32. CytomX Therapeutics had a negative net margin of 208.92% and a negative return on equity of 59.65%. The business had revenue of $11.65 million during the quarter, compared to analysts’ expectations of $2.10 million. Equities research analysts expect that CytomX Therapeutics, Inc. will post ($1.46) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “CytomX Therapeutics, Inc. (CTMX) Stake Held by Eventide Asset Management LLC” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://sportsperspectives.com/2017/06/20/cytomx-therapeutics-inc-ctmx-stake-held-by-eventide-asset-management-llc.html.
A number of research analysts have issued reports on the stock. Jefferies Group LLC restated a “buy” rating and set a $25.00 target price on shares of CytomX Therapeutics in a research report on Tuesday, June 6th. Zacks Investment Research lowered shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, May 29th. ValuEngine lowered shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 11th. HC Wainwright reiterated a “buy” rating on shares of CytomX Therapeutics in a research report on Monday, May 8th. Finally, Cann reiterated a “hold” rating on shares of CytomX Therapeutics in a research report on Thursday, March 30th. Two analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. CytomX Therapeutics has a consensus rating of “Hold” and a consensus price target of $24.50.
In other CytomX Therapeutics news, major shareholder Rock Ventures Lp Third sold 1,650,000 shares of the business’s stock in a transaction that occurred on Monday, March 27th. The shares were sold at an average price of $17.39, for a total value of $28,693,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Sean A. Mccarthy sold 4,781 shares of the business’s stock in a transaction that occurred on Monday, May 1st. The stock was sold at an average price of $15.70, for a total transaction of $75,061.70. Following the completion of the transaction, the insider now directly owns 6,760 shares of the company’s stock, valued at approximately $106,132. The disclosure for this sale can be found here. In the last three months, insiders sold 1,693,000 shares of company stock valued at $29,401,640. Corporate insiders own 8.00% of the company’s stock.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.